SecBot SecBot
Biotech Drug Report Generated Nov 9, 2026

PN-477

PTGX·Protagonist Therapeutics, Inc
NEUTRAL
Drug Impact Rating4/10
Trial phase
Preclinical (development candidate nominated)
Time to market
Years away. PN-477 is preclinical with no IND filed as of November 2026. If development proceeds, Phase 1 initiation would be at least 12-18 months out, and potential approval (if successful) would be 5+ years away.
Why 4/10
PN-477 is a preclinical development candidate with no IND filing, clinical trial start, or regulatory decision scheduled. There is no hard dated catalyst in the next ~12 months, so the impact score defaults to 4 and is capped at 5 per the rubric.
Actionable Insight NEUTRAL

PN-477 is a preclinical-stage asset with no IND filing or clinical trial start announced as of November 2026. Watch for IND filing or Phase 1 initiation updates, but the stock's near-term value is driven by commercial execution of ICOTYDE and MIMRYLO, not this early-stage candidate.

Price Chart

Loading chart...

Executive Summary

PN-477 is a wholly-owned preclinical development candidate from Protagonist Therapeutics (PTGX), an oral and injectable GLP-1/GIP/glucagon triple receptor agonist peptide for obesity. It was nominated as a development candidate in June 2025 and remains in preclinical stages as of the company's Q3 2026 update (November 5, 2026). Protagonist is now a profitable, royalty-driven biotech with two FDA-approved drugs (ICOTYDE for psoriasis, MIMRYLO/rusfertide for polycythemia vera) and a deep pipeline including PN-881 (Phase 2b oral IL-17 antagonist). PN-477 is a small, early-stage part of the portfolio with no IND filed or clinical data yet, making it a long-duration option on the obesity market rather than a near-term value driver.

How It Works

PN-477 is a peptide drug that simultaneously activates three gut hormone receptors: GLP-1R, GIPR, and GCGR. This triple-action approach is designed to reduce appetite, increase energy expenditure, and improve blood sugar control for weight loss. It is being developed in both a daily pill form (oral) and a shot (subcutaneous), aiming to match the efficacy of leading injectable obesity drugs while offering more convenient dosing options.

Trial Status

PN-477 was selected as a development candidate in June 2025 after demonstrating "optimal absolute and relative activity against all three hormone receptors in preclinical testing," per management. It has not yet entered IND-enabling studies or clinical trials. The company's Q3 2026 corporate update did not highlight any specific PN-477 milestones, suggesting it remains in early preclinical development.

The Two-Sided Case

▲ Bull Case4
PN-477 is a triple GLP-1/GIP/GCG receptor agonist with both oral and subcutaneous routes, potentially offering best-in-class weight loss and patient convenience if preclinical promise translates to humans.
Protagonist has deep expertise in oral peptide discovery, having already brought two drugs to FDA approval (ICOTYDE, MIMRYLO), which de-risks the platform.
The obesity market is massive (projected $100B+ annually), and an oral triple agonist could capture significant share if it matches injectable efficacy.
Protagonist is now profitable with $678.8M+ in cash (as of late 2025) and a $300M buyback authorized, providing ample resources to fund PN-477's development without dilution.
▼ Bear Case4
PN-477 is preclinical and years away from any revenue, with no guarantee it will ever reach clinical trials or prove safe/efficacious in humans.
The obesity market is intensely competitive with established players Novo Nordisk (Wegovy/Ozempic), Eli Lilly (Zepbound/Mounjaro), and many other triple agonists in development, making differentiation difficult.
Protagonist's focus is currently on commercializing ICOTYDE and MIMRYLO and advancing PN-881 (Phase 2b), so PN-477 may receive limited resources near-term.
As a wholly-owned preclinical candidate, all development costs and risks fall on Protagonist with no partner to share the burden.

Upcoming Catalysts

  • IND filing (no date announced)
  • Phase 1 clinical trial initiation (no date announced)
  • Preclinical data presentations at scientific conferences

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Protagonist Therapeutics, Inc 8-K PTGX ·Originating report

Sources · 6

Hover a chip for the title
1 jconline.com2 newswire.com3 usatoday.com4 finanznachrichten.de5 weatherforddemocrat.com6 msn.com